<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: competitors", fill: "#bf00ff"},
{source: "4: competitors", target: "4: manufacture use", fill: "#bf00ff"},
{source: "4: manufacture use", target: "4: United States ", fill: "#bf00ff"},
{source: "4: competitors", target: "6: adverse ruling", fill: "#dda0dd"},
{source: "6: adverse ruling", target: "6: significantly", fill: "#dda0dd"},
{source: "6: adverse ruling", target: "12: International ", fill: "#8a496b"},
{source: "12: International ", target: "12: sales consisting", fill: "#8a496b"},
{source: "12: sales consisting", target: "12: sales from", fill: "#8a496b"},
{source: "12: sales from", target: "12: subsidiaries", fill: "#8a496b"},
{source: "12: subsidiaries", target: "12: Germany Spain Italy France and Japan ", fill: "#8a496b"},
{source: "12: Germany Spain Italy France and Japan ", target: "12: international", fill: "#8a496b"},
{source: "12: international", target: "12: the United States ", fill: "#8a496b"},
{source: "12: the United States ", target: "12: will continue", fill: "#8a496b"},
{source: "12: will continue", target: "12: significant", fill: "#8a496b"},
{source: "12: International ", target: "15: risks associated with international sales", fill: "#d70040"},
{source: "15: risks associated with international sales", target: "15: currently face", fill: "#d70040"},
{source: "15: currently face", target: "15: longer payment cycles common", fill: "#d70040"},
{source: "15: longer payment cycles common", target: "15: significant delays", fill: "#d70040"},
{source: "15: significant delays", target: "15: necessary", fill: "#d70040"},
{source: "15: necessary", target: "15: foreign regulatory approvals", fill: "#d70040"},
{source: "15: foreign regulatory approvals", target: "15: difficulties", fill: "#d70040"},
{source: "15: difficulties", target: "15: foreign operations", fill: "#d70040"},
{source: "15: foreign operations", target: "15: Alexandrite ", fill: "#d70040"},
{source: "15: Alexandrite ", target: "15: GentleLASE ", fill: "#d70040"},
{source: "15: GentleLASE ", target: "15: manufacture", fill: "#d70040"},
{source: "15: manufacture", target: "15: GentleLASE ", fill: "#d70040"},
{source: "15: risks associated with international sales", target: "17: exclusively on", fill: "#e25822"},
{source: "17: exclusively on", target: "17: contract manufacturer", fill: "#e25822"},
{source: "17: contract manufacturer", target: "17: alternative supplier meeting", fill: "#e25822"},
{source: "17: alternative supplier meeting", target: "17: quality standards", fill: "#e25822"},
{source: "17: exclusively on", target: "20: Disappointing ", fill: "#00416a"},
{source: "20: Disappointing ", target: "20: quarterly revenue", fill: "#00416a"},
{source: "20: quarterly revenue", target: "20: common stock", fill: "#00416a"},
{source: "20: Disappointing ", target: "21: difficult", fill: "#c66"},
{source: "21: difficult", target: "21: sharply from quarter", fill: "#c66"},
{source: "21: difficult", target: "25: quarterly revenue", fill: "#87ceeb"},
{source: "25: quarterly revenue", target: "25: difficult", fill: "#87ceeb"},
{source: "25: difficult", target: "25: potential increases", fill: "#87ceeb"},
{source: "25: potential increases", target: "25: price competition", fill: "#87ceeb"},
{source: "25: price competition", target: "25: competition", fill: "#87ceeb"},
{source: "25: competition", target: "25: competitors", fill: "#87ceeb"},
{source: "25: competitors", target: "25: potential decrease", fill: "#87ceeb"},
{source: "25: potential decrease", target: "25: possible delays", fill: "#87ceeb"},
{source: "25: possible delays", target: "25: market acceptance", fill: "#87ceeb"},
{source: "25: market acceptance", target: "25: extensions", fill: "#87ceeb"},
{source: "25: extensions", target: "25: customers budgeting", fill: "#87ceeb"},
{source: "25: customers budgeting", target: "25: product sales", fill: "#87ceeb"},
{source: "25: product sales", target: "25: anticipation", fill: "#87ceeb"},
{source: "25: anticipation", target: "25: product introductions", fill: "#87ceeb"},
{source: "25: product introductions", target: "25: enhancements by us", fill: "#87ceeb"},
{source: "25: enhancements by us", target: "25: operations", fill: "#87ceeb"},
{source: "25: operations", target: "25: significant product backlogs", fill: "#87ceeb"},
{source: "25: significant product backlogs", target: "25: effectiveness", fill: "#87ceeb"},
{source: "25: effectiveness", target: "25: manufacturing process", fill: "#87ceeb"},
{source: "25: manufacturing process", target: "25: distribution channels service", fill: "#87ceeb"},
{source: "25: distribution channels service", target: "25: customer support organizations", fill: "#87ceeb"},
{source: "25: customer support organizations", target: "25: acquisitions", fill: "#87ceeb"},
{source: "25: acquisitions", target: "25: technology", fill: "#87ceeb"},
{source: "25: technology", target: "25: laser industry could", fill: "#87ceeb"},
{source: "25: laser industry could", target: "25: lasers obsolete", fill: "#87ceeb"},
{source: "25: quarterly revenue", target: "26: cosmetic laser equipment industry", fill: "#e25098"},
{source: "26: cosmetic laser equipment industry", target: "26: technological", fill: "#e25098"},
{source: "26: technological", target: "26: development", fill: "#e25098"},
{source: "26: development", target: "26: product innovations", fill: "#e25098"},
{source: "26: cosmetic laser equipment industry", target: "28: financial condition", fill: "#da1d81"},
{source: "28: financial condition", target: "28: products fail", fill: "#da1d81"},
{source: "28: products fail", target: "28: compete favorably", fill: "#da1d81"},
{source: "28: compete favorably", target: "28: technological developments", fill: "#da1d81"},
{source: "28: technological developments", target: "28: competitors new product introductions", fill: "#da1d81"},
{source: "28: competitors new product introductions", target: "28: product price", fill: "#da1d81"},
{source: "28: product price", target: "28: reductions", fill: "#da1d81"},
{source: "28: financial condition", target: "32: medical devices", fill: "#9bddff"},
{source: "32: medical devices", target: "32: United States ", fill: "#9bddff"},
{source: "32: United States ", target: "32: generally", fill: "#9bddff"},
{source: "32: generally", target: "32: advance from", fill: "#9bddff"},
{source: "32: advance from", target: "32: United States Food and Drug Administration FDA ", fill: "#9bddff"},
{source: "32: United States Food and Drug Administration FDA ", target: "32: Federal Food Drug and Cosmetic Act", fill: "#9bddff"},
{source: "32: medical devices", target: "37: approval process upon one", fill: "#9f1d35"},
{source: "37: approval process upon one", target: "37: future products nor", fill: "#9f1d35"},
{source: "37: future products nor", target: "37: approval will ever", fill: "#9f1d35"},
{source: "37: approval process upon one", target: "40: retroactively decide", fill: "#ffa6c9"},
{source: "40: retroactively decide", target: "40: modifications", fill: "#ffa6c9"},
{source: "40: modifications", target: "40: marketing andor recall", fill: "#ffa6c9"},
{source: "40: marketing andor recall", target: "40: modified products", fill: "#ffa6c9"},
{source: "40: retroactively decide", target: "42: The FDA ", fill: "#e66771"},
{source: "42: The FDA ", target: "42: manufacturer", fill: "#e66771"},
{source: "42: manufacturer", target: "42: determination", fill: "#e66771"},
{source: "42: determination", target: "42: instance but", fill: "#e66771"},
{source: "42: instance but", target: "42: such decision", fill: "#e66771"},
{source: "42: The FDA ", target: "46: Achieving ", fill: "#534b4f"},
{source: "46: Achieving ", target: "46: compliance with", fill: "#534b4f"},
{source: "46: compliance with", target: "46: regulations", fill: "#534b4f"},
{source: "46: regulations", target: "46: difficult", fill: "#534b4f"},
{source: "46: difficult", target: "46: enforcement action", fill: "#534b4f"},
{source: "46: Achieving ", target: "59: could incur", fill: "#004b49"},
{source: "59: could incur", target: "59: product liability", fill: "#004b49"},
{source: "59: could incur", target: "63: product liability", fill: "#7df9ff"},
{source: "63: product liability", target: "63: policy will provide sufficient", fill: "#7df9ff"},
{source: "63: policy will provide sufficient", target: "63: such insurance coverage on", fill: "#7df9ff"},
{source: "63: such insurance coverage on", target: "63: economic terms", fill: "#7df9ff"},
{source: "63: product liability", target: "82: effective", fill: "#536878"},
{source: "82: effective", target: "82: internal control over financial", fill: "#536878"},
{source: "82: internal control over financial", target: "82: such internal control", fill: "#536878"},
{source: "82: effective", target: "START_HERE", fill: "#536878"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Luhansk_International_Airport">Luhansk International Airport</a></td>
      <td>Luhansk International Airport (Ukrainian: Міжнародний аеропорт "Луганськ") was an airport in Luhansk, Ukraine (IATA: VSG, ICAO: UKCW). The airport was located 20 km (12 miles) south of the city center, 9 km to the city limit.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Necessary_But_Not_Sufficient">Necessary But Not Sufficient</a></td>
      <td>In logic and mathematics, necessity and sufficiency are terms used to describe a conditional or implicational relationship between two statements. For example, in the conditional statement: "If P then Q", Q is necessary for P, because the truth of Q is guaranteed by the truth of P (equivalently, it is impossible to have P without Q).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chrysoberyl">Chrysoberyl</a></td>
      <td>The mineral or gemstone chrysoberyl is an aluminate of beryllium with the formula BeAl2O4. The name chrysoberyl is derived from the Greek words χρυσός chrysos and βήρυλλος beryllos, meaning "a gold-white spar".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sapphire">Sapphire</a></td>
      <td>Sapphire is a precious gemstone, a variety of the mineral corundum, consisting of aluminium oxide (α-Al2O3) with trace amounts of elements such as iron, titanium, chromium, vanadium, or magnesium. The name sapphire is derived from the Latin "saphirus" and the Greek "sapheiros", both of which mean blue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_hair_removal">Laser hair removal</a></td>
      <td>Laser hair removal is the process of hair removal by means of exposure to pulses of laser light that destroy the hair follicle. It had been performed experimentally for about twenty years before becoming commercially available in 1995 and 1996.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contract">Contract</a></td>
      <td>A contract is a legally enforceable agreement that creates, defines, and governs mutual rights and obligations among its parties. A contract typically involves the transfer of goods, services, money, or a promise to transfer any of those at a future date.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brian_Humphries_(IT_businessman)">Brian Humphries (IT businessman)</a></td>
      <td>Brian Humphries is a businessman who is currently the CEO of Cognizant. He replaced Francisco D'Souza as the CEO of Cognizant on April 1, 2019.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/FIS_(company)">FIS (company)</a></td>
      <td>FIS is an American multinational corporation which offers a wide range of financial products and services. FIS is most known for its development of Financial Technology, or FinTech, and as of Q2 2020 it offers its solutions in three primary segments: Merchant Solutions, Banking Solutions, and Capital Market Solutions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Earnings_guidance">Earnings guidance</a></td>
      <td>In financial reporting, earnings guidance or simply guidance is a publicly traded corporation's official prediction of its own near-future profit or loss, stated as an amount of money per share; see Earnings call.  \nEarnings guidance is usually a financial forecast presented as a quarterly report of the corporation's performance in the next quarter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_(song)">Difficult (song)</a></td>
      <td>"Difficult" is the fourth single from French-American recording artist Uffie's debut album, Sex Dreams and Denim Jeans. The single was produced by Uffie's label-mate and friend SebastiAn and was released by Ed Banger Records, Because Music and Elektra Records on October 18, 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Center_for_Regulatory_Effectiveness">Center for Regulatory Effectiveness</a></td>
      <td>The Center for Regulatory Effectiveness (CRE) is an industry-funded, for-profit think tank. It focuses on federal agency compliance with "good government" laws which regulate the regulators.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alcoholics_Anonymous">Alcoholics Anonymous</a></td>
      <td>Alcoholics Anonymous (AA) is an international mutual aid fellowship dedicated to abstinence based recovery from alcoholism through its spiritually inclined Twelve Step program. Following its Twelve Traditions, AA and autonomous AA groups are self-supporting through the strictly voluntary contributions from members only.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Efficacy">Efficacy</a></td>
      <td>Efficacy is the ability to perform a task to a satisfactory or expected degree. The word comes from the same roots as effectiveness, and it has often been used synonymously, although in pharmacology a distinction is now often made between efficacy and effectiveness.The word efficacy is used in pharmacology and medicine to refer both to the maximum response achievable from a pharmaceutical drug in research settings, and to the capacity for sufficient therapeutic effect or beneficial change in clinical settings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generally_recognized_as_safe">Generally recognized as safe</a></td>
      <td>Generally recognized as safe (GRAS) is a United States Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts under the conditions of its intended use. An ingredient with a GRAS designation is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Derivative_(finance)">Derivative (finance)</a></td>
      <td>In finance, a derivative is a contract that derives its value from the performance of an underlying entity. This underlying entity can be an asset, index, or interest rate, and is often simply called the "underlying".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Modifications_(genetics)">Modifications (genetics)</a></td>
      <td>\n== Genetic Modifications (Incidental and Intentional) ==\n\nModifications are changes in an individual's DNA due to incidental mutation or intentional genetic modification using various biotechnologies. Although confusion exists between the terms "modification" and "mutation" as they are often used interchangeably, modification differentiates itself from mutation because it acts as an umbrella term, encompassing both definitions of mutation and genetic engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Body_modification">Body modification</a></td>
      <td>Body modification (or body alteration) is the deliberate altering of the human anatomy or human physical appearance.  In its broadest definition it includes skin tattooing, socially acceptable decoration (e.g., common ear piercing in many societies), and religious rites of passage (e.g., circumcision in a number of cultures), as well as the modern primitive movement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Post-translational_modification">Post-translational modification</a></td>
      <td>Post-translational modification (PTM) refers to the covalent and generally enzymatic modification of proteins following protein biosynthesis. This process occurs in the endoplasmic reticulum and the golgi apparatus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerial_stem_modification">Aerial stem modification</a></td>
      <td>Aerial stem modifications are modifications to the aerial stems, vegetative buds and floral buds of plants growing in different conditions and which perform functions such as climbing, protection, support, synthesis of food, or vegetative propagation. Aerial stem structures that undergo modifications to perform these special functions include tendrils, thorns, hooks, phylloclade, tuberous stems and bulbils.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Robert_Califf">Robert Califf</a></td>
      <td>Robert McKinnon Califf (born 1951) is an American cardiologist who currently serves as the commissioner of the Food and Drug Administration.    \nHe was first nominated to be commissioner in September 2015  by President Barack Obama and he was confirmed by the U.S. Senate in February 2016, serving until January 20, 2017.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Compliance_(psychology)">Compliance (psychology)</a></td>
      <td>Compliance is a response—specifically, a submission—made in reaction to a request.  The request may be explicit (e.g., foot-in-the-door technique) or implicit (e.g., advertising).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strict_liability">Strict liability</a></td>
      <td>In  criminal  and  civil law, strict liability is a standard of liability under which a person is legally responsible for the consequences flowing from an activity even in the absence of fault or criminal intent on the part of the defendant.\nUnder the strict liability law, if the defendant possesses anything that is inherently dangerous, as specified under the "ultrahazardous" definition, the defendant is then strictly liable for any damages caused by such possession, no matter how careful the defendant is safeguarding them.In the field of torts, prominent examples of strict liability may include product liability, abnormally dangerous activities (e.g., blasting), intrusion onto another's land by livestock, and ownership of wild animals.Other than activities specified above (like ownership of wild animals, etc), US courts also consider the following activities as "ultrahazardous":\nstoring flammable liquids in quantity in an urban area\npile driving\nblasting\ncrop dusting\nfumigation with cyanide gas\nemission of noxious fumes by a manufacturing plant located in a settled area\nlocating oil wells or refineries in populated communities\ntest firing solid-fuel rocket motors.On the other hand, US courts rule the following activities as not "ultrahazardous": parachuting, drunk driving, maintaining power lines, and letting water escape from an irrigation ditch.Traditional criminal offenses that require no element of intent (mens rea) include statutory rape and felony murder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tort">Tort</a></td>
      <td>A Tory () is a person who holds a political philosophy known as Toryism, based on a British version of traditionalism and conservatism, which upholds the supremacy of social order as it has evolved in the English culture throughout history. The Tory ethos has been summed up with the phrase "God, Queen, and Country".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_countries_by_health_insurance_coverage">List of countries by health insurance coverage</a></td>
      <td>A list of countries by health insurance coverage. The table lists the percentage of the total population covered by total public and primary private health insurance, by government/social health insurance, and by primary private health insurance, including 34 members of Organisation for Economic Co-operation and Development (OECD) member countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_insurance_coverage_in_the_United_States">Health insurance coverage in the United States</a></td>
      <td>Health insurance coverage in the United States is provided by several public and private sources. During 2019, the U.S. population overall was approximately 330 million, with 59 million people 65 years of age and over covered by the federal Medicare program.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internal_control">Internal control</a></td>
      <td>Internal control, as defined by accounting and auditing, is a process for assuring of an organization's objectives in operational effectiveness and efficiency, reliable financial reporting, and compliance with laws, regulations and policies. A broad concept, internal control involves everything that controls risks to an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Locus_of_control">Locus of control</a></td>
      <td>Locus of control is the degree to which people believe that they, as opposed to external forces (beyond their influence), have control over the outcome of events in their lives. The concept was developed by Julian B. Rotter in 1954, and has since become an aspect of personality psychology.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CANDELA CORP /DE/      Item 1A                <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>The  following important factors, among others, could cause our actual     operating results to <font color="blue">differ materially from</font> those indicated or suggested by     forward-looking statements made in this Form 10-K or <font color="blue">presented elsewhere by</font>     <font color="blue"><font color="blue">management</font> from</font> time to time</td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>results in our <font color="blue">intellectual property <font color="blue">litigation</font> with</font> <font color="blue">Palomar  </font>   Medical Technologies may result in <font color="blue"><font color="blue">significant</font> decline</font> to our stock price</td>
    </tr>
    <tr>
      <td>On August 9, 2006, one of our <font color="blue">competitors</font>, Palomar Medical Technologies     (“Palomar”), alleged that the <font color="blue">manufacture</font>, use and sale of our products for     laser  hair  removal  infringe  a certain <font color="blue"><font color="blue">United States</font> </font>patent</td>
    </tr>
    <tr>
      <td><font color="blue">Public     </font><font color="blue">announcements concerning</font> this <font color="blue">litigation</font> that are unfavorable to us may     result in <font color="blue"><font color="blue">significant</font> decline</font>s in our stock price</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse ruling</font> or     judgment  in  this  matter  could  cause  our  stock  price to decline     <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation  </font>with  <font color="blue">Palomar  </font>will  be  expensive and protracted, and our     <font color="blue">intellectual property position may</font> be <font color="blue">weakened as</font> a result of an adverse     ruling  or  judgment</td>
    </tr>
    <tr>
      <td>Whether or not we are successful in the pending     lawsuits, <font color="blue">litigation</font> consumes substantial amounts of our <font color="blue">financial resources</font>     and diverts <font color="blue">management</font>’s attention away from our core business</td>
    </tr>
    <tr>
      <td><font color="blue">See Item     </font>3—“Legal Proceedings</td>
    </tr>
    <tr>
      <td>”       Because we derive more than half of our <font color="blue">revenue from</font> <font color="blue">international</font> sales,     including approximately 20prca of our <font color="blue">revenue from</font> Japan and the Asia-Pacific     marketplace in fiscal 2006, we are susceptible to <font color="blue"><font color="blue">currency fluctuation</font>s</font>,     negative  economic  changes taking place in Japan and the Asia-Pacific     marketplace, and other <font color="blue">risks associated with conducting</font> business overseas</td>
    </tr>
    <tr>
      <td>We sell more than half of our products and <font color="blue">services outside</font> the United     States</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales, consisting of <font color="blue">sales from</font> our <font color="blue">subsidiaries</font> in     Germany, Spain, Italy, France and Japan, and sales shipped directly to     <font color="blue">international</font> locations from the <font color="blue">United States</font>, accounted for 56prca of our     revenue for <font color="blue">fiscal year</font> 2006, and we expect that they <font color="blue">will continue</font> to be     <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>As a result, a major part of our revenues and operating results     could be <font color="blue">adversely</font> affected by risks associated with <font color="blue">international</font> sales</td>
    </tr>
    <tr>
      <td>In     particular, <font color="blue">significant</font> fluctuations in the <font color="blue">exchange rates between</font> the     <font color="blue"><font color="blue">United States</font> </font>dollar and <font color="blue">foreign currencies could</font> cause us to lower our     prices  and  thus reduce our <font color="blue">profitability</font>, or could cause prospective     customers to push       18     ______________________________________________________________________       out orders to <font color="blue">later dates</font> because of the <font color="blue">increased relative cost</font> of our     products in the aftermath of a <font color="blue">currency d<font color="blue">evaluation</font></font> or <font color="blue">currency fluctuation</font></td>
    </tr>
    <tr>
      <td>Other risks associated with <font color="blue">international</font> sales that we <font color="blue">currently face</font> or     have faced in the past include:       ·       <font color="blue">longer payment cycles common</font> in foreign markets       ·       failure to obtain or <font color="blue">significant</font> delays in obtaining <font color="blue">necessary</font>     import or <font color="blue">foreign <font color="blue">regulatory</font> approvals</font> for our products       ·       <font color="blue"><font color="blue">difficult</font>ies</font> in staffing and managing our <font color="blue">foreign <font color="blue">operations</font></font>       The failure to obtain <font color="blue">Alexandrite </font>rods for the GentleLASE® system from our     sole  supplier  would  impair  our ability to <font color="blue">manufacture</font> and sell the     GentleLASE® system</td>
    </tr>
    <tr>
      <td>We  use  <font color="blue">Alexandrite </font>rods to <font color="blue">manufacture</font> the GentleLASE® system, which     <font color="blue">accounts</font>  for  a  <font color="blue">significant</font> portion of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>We depend     <font color="blue">exclusively on</font> our contract <font color="blue">manufacture</font>r to supply these rods, for which no     <font color="blue">alternative supplier meeting</font> our <font color="blue">quality standards</font> exists</td>
    </tr>
    <tr>
      <td>We cannot be     certain that our contract <font color="blue">manufacture</font>r will be able to meet our future     <font color="blue"><font color="blue">requirements</font> at current prices</font> or at all</td>
    </tr>
    <tr>
      <td>To date, we have been able to     obtain <font color="blue">adequate supplies</font> of <font color="blue">Alexandrite </font>rods in a timely manner, but any     <font color="blue">extended interruption</font> in our <font color="blue">supplies <font color="blue">could hurt</font></font> our results</td>
    </tr>
    <tr>
      <td><font color="blue">Disappointing </font><font color="blue">quarterly revenue</font> or operating results could cause the price     of our <font color="blue">common stock</font> to fall</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly revenue</font> and operating results are <font color="blue">difficult</font> to predict and may     swing  <font color="blue">sharply from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>Historically, our <font color="blue">first fiscal</font>     quarter has typically had the <font color="blue">least amount</font> of revenue in any quarter of our     <font color="blue">fiscal year</font></td>
    </tr>
    <tr>
      <td>The results of the <font color="blue">first quarter</font> are <font color="blue">directly impacted by</font> the     <font color="blue">seasonality</font> of the <font color="blue">purchasing cycle</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">quarterly revenue</font> or operating results fall below the <font color="blue">expectations</font> of     investors or <font color="blue">public market analysts</font>, the price of our <font color="blue">common stock</font> could     <font color="blue">fall substantially</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly revenue</font> is <font color="blue">difficult</font> to forecast for many     reasons, some of which are outside of our control, including the following:       Market supply and demand       ·       <font color="blue">potential increases</font> in the level and intensity of <font color="blue">price <font color="blue">competition</font></font>     between our <font color="blue">competitors</font> and us       ·       <font color="blue">potential decrease</font> in demand for our products       ·       <font color="blue">possible delays</font> in <font color="blue">market acceptance</font> of our new products       Customer behavior       ·       changes in or <font color="blue">extensions</font> of our customers’ budgeting and purchasing     cycles       ·        changes in the timing of <font color="blue">product sales</font> in <font color="blue">anticipation</font> of new     <font color="blue">product introductions</font> or <font color="blue">enhancements by us</font> or our <font color="blue">competitors</font>       Company <font color="blue">operations</font>       ·       absence of <font color="blue">significant</font> product backlogs       ·       our <font color="blue"><font color="blue">effective</font>ness</font> in our <font color="blue">manufacturing process</font>       ·       unsatisfactory performance of our distribution channels, service     providers, or <font color="blue">customer support organizations</font>       ·       timing of any <font color="blue"><font color="blue">acquisition</font>s</font> and related costs       19     ______________________________________________________________________       Our  failure  to  respond  to  rapid changes in <font color="blue">technology</font> and intense     <font color="blue">competition</font> in the <font color="blue"><font color="blue">laser industry</font> could</font> make our <font color="blue">lasers obsolete</font></td>
    </tr>
    <tr>
      <td>The aesthetic and <font color="blue">cosmetic laser equipment industry</font> is subject to rapid and     substantial  <font color="blue">technological</font>  <font color="blue">development</font> and <font color="blue">product innovations</font></td>
    </tr>
    <tr>
      <td>To be     successful, we must be responsive to new <font color="blue">development</font>s in laser <font color="blue">technology</font>     and <font color="blue">new <font color="blue">applications</font></font> of existing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial condition</font> and     operating results could be hurt if our <font color="blue">products fail</font> to <font color="blue">compete favorably</font> in     response  to  such  <font color="blue">technological</font> <font color="blue">development</font>s, or we are not agile in     responding  to <font color="blue">competitors</font>’ new <font color="blue">product introductions</font> or <font color="blue">product price</font>     <font color="blue">reductions</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">compete against numerous companies offering</font>     products similar to ours, some of which have greater financial, marketing,     and <font color="blue">technical resources than</font> we do</td>
    </tr>
    <tr>
      <td>We cannot be sure that we will be able     to <font color="blue">compete <font color="blue">successfully</font> with</font> these companies and our failure to do so could     hurt our business, <font color="blue">financial condition</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Like other companies in our industry, we are subject to a <font color="blue"><font color="blue">regulatory</font> review</font>     process  and our failure to receive <font color="blue">necessary</font> <font color="blue">government</font> clearances or     approvals  could  affect  our  ability to sell our products and remain     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>The types of <font color="blue">medical devices</font> that we seek to market in the <font color="blue"><font color="blue">United States</font> </font>    <font color="blue">generally</font>  must receive either “510(k) clearance” or “PMA approval” in     <font color="blue">advance from</font> the <font color="blue"><font color="blue">United States</font> </font>Food and Drug Administration (FDA) pursuant     to the Federal Food, Drug, and Cosmetic Act</td>
    </tr>
    <tr>
      <td>The FDA’s 510(k) clearance     <font color="blue">process usually</font> takes from four to twelve months, but it can <font color="blue">last longer</font></td>
    </tr>
    <tr>
      <td>The process of obtaining PMA approval is much more costly and uncertain and     <font color="blue">generally</font> takes from one to <font color="blue">three years</font> or <font color="blue">even longer</font></td>
    </tr>
    <tr>
      <td>To date, the FDA has     deemed our <font color="blue">products eligible</font> for the 510(k) clearance process</td>
    </tr>
    <tr>
      <td>We believe     that most of our products in <font color="blue">development</font> will receive similar treatment</td>
    </tr>
    <tr>
      <td>However, we cannot be sure that the FDA will not impose the more burdensome     PMA <font color="blue">approval process upon one</font> or more of our future products, nor can we be     sure that 510(k) clearance or PMA <font color="blue">approval will ever</font> be obtained for any     product we propose to market</td>
    </tr>
    <tr>
      <td>Many <font color="blue">foreign countries</font> in which we market or may market our products have     <font color="blue"><font color="blue">regulatory</font> bodies</font> and <font color="blue">restrictions</font> similar to those of the FDA We cannot be     certain that we will be able to obtain (or continue to obtain) any such     <font color="blue">government</font>  approvals  or  <font color="blue">successfully</font>  comply  with any <font color="blue">such foreign</font>     <font color="blue">regulations</font>  in a timely and cost-<font color="blue">effective</font> manner, if at all, and our     failure to do so could <font color="blue">adversely</font> affect our ability to sell our products</td>
    </tr>
    <tr>
      <td>We have modified some of our <font color="blue">products without</font> FDA clearance</td>
    </tr>
    <tr>
      <td>The FDA could     <font color="blue">retroactively decide</font> the <font color="blue"><font color="blue">modification</font>s</font> were improper and require us to cease     marketing and/or recall the <font color="blue">modified products</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue">modification</font>  to  one  of  our  510(k) cleared devices that could     <font color="blue"><font color="blue">significant</font>ly</font> affect its safety or <font color="blue"><font color="blue">effective</font>ness</font>, or that <font color="blue">would constitute</font> a     major change in its <font color="blue">intended use</font>, requires a new 510(k) clearance</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>requires  every  <font color="blue">manufacture</font>r  to make this <font color="blue">determination</font> in the first     instance, but the FDA can review any <font color="blue">such decision</font></td>
    </tr>
    <tr>
      <td>We have modified some of     our marketed devices, but we believe that new 510(k) clearances are not     required</td>
    </tr>
    <tr>
      <td>We cannot be certain that the FDA <font color="blue">would agree with</font> any of our     <font color="blue">decisions</font> not to seek 510(k) clearance</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>requires us to seek     510(k) clearance for any <font color="blue">modification</font>, we also may be required to cease     marketing  and/or  recall  the  modified  device until we obtain a new     510(k) clearance</td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font>complete <font color="blue">compliance with</font> FDA <font color="blue">regulations</font> is <font color="blue">difficult</font>, and if we     fail to comply, we could be subject to FDA <font color="blue">enforcement action</font></td>
    </tr>
    <tr>
      <td>We are subject to inspection and <font color="blue">market surveillance by</font> the FDA to determine     <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">regulatory</font> scheme is     complex, especially the Quality System Regulation (“QSR”), which requires     <font color="blue">manufacture</font>rs to follow elaborate design, testing, control, documentation,     and other <font color="blue">quality assurance procedures</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">complexity</font> makes complete     compliance <font color="blue">difficult</font> to achieve</td>
    </tr>
    <tr>
      <td>Also, the <font color="blue">determination</font> as to whether <font color="blue">a QSR     </font>violation has occurred is <font color="blue">often subjective</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that we have     failed to <font color="blue">comply with</font> the QSR or other applicable <font color="blue">requirements</font>, the agency       20     ______________________________________________________________________       can institute a wide variety of <font color="blue">enforcement action</font>s, including a public     <font color="blue">warning letter</font> or other stronger remedies, such as:       ·       fines, injunctions, and <font color="blue">civil penalties against us</font>       ·       recall or seizure of our products       ·       operating <font color="blue">restrictions</font>, partial suspension, or <font color="blue">total shutdown</font> of our     production       ·       refusing our requests for 510(k) clearance or PMA approval of new     products       ·       <font color="blue">withdrawing product approvals already granted</font>       ·       <font color="blue">criminal prosecution</font>       <font color="blue">Claims  </font>by  others  that  our <font color="blue">products infringe</font> their patents or other     <font color="blue">intellectual property rights</font> could prevent us from manufacturing and selling     some  of  our  products  or require us to incur substantial <font color="blue">costs from</font>     <font color="blue">litigation</font> or <font color="blue">development</font> of non-infringing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our industry has been characterized by frequent <font color="blue">litigation</font> regarding patent     and other <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">applications</font> are maintained     in  secrecy in the <font color="blue"><font color="blue">United States</font> </font><font color="blue">until such patents</font> are issued and are     maintained  in secrecy for a period of time outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Accordingly, we can <font color="blue">conduct only</font> limited searches to determine whether our     <font color="blue">technology</font> infringes any patents or patent <font color="blue">applications</font> of others</td>
    </tr>
    <tr>
      <td>Any     claims of patent infringement would be time-consuming and could:       ·       result in costly <font color="blue">litigation</font>       ·       divert our technical and <font color="blue"><font color="blue">management</font> personnel</font>       ·       cause <font color="blue">product shipment delays</font>       ·       require us to develop non-infringing <font color="blue">technology</font>       ·       require us to <font color="blue">enter into royalty</font> or <font color="blue">licensing agreements</font>       Although patent and <font color="blue">intellectual property disputes</font> in the <font color="blue">laser industry</font>     have often been settled through licensing or similar arrangements, costs     <font color="blue">associated with such arrangements may</font> be substantial and often require the     payment  of  ongoing royalties, which <font color="blue">could hurt</font> our gross margins</td>
    </tr>
    <tr>
      <td>In     addition, we cannot be sure that the <font color="blue">necessary</font> licenses would be available     to us on satisfactory terms, or that we <font color="blue">could redesign</font> our products or     processes to <font color="blue">avoid infringement</font>, if <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Accordingly, an adverse     <font color="blue">determination</font> in a judicial or <font color="blue">administrative proceeding</font>, or the failure to     obtain <font color="blue">necessary</font> licenses, could prevent us from manufacturing and selling     some of our products, which <font color="blue">could hurt</font> our business, results of <font color="blue">operations</font>,     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>On the other hand, we may have to <font color="blue">start costly</font> and     time consuming <font color="blue">litigation</font> in order to enforce our patents, to <font color="blue">protect trade</font>     secrets, and know-how owned by us or to determine the enforceability, scope,     and validity of the <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial costs as a result of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>There are <font color="blue">various risks</font> of <font color="blue">physical injury</font> to the patient when using our     lasers for aesthetic and <font color="blue">cosmetic treatments</font></td>
    </tr>
    <tr>
      <td>Injuries often result in     <font color="blue">product <font color="blue">liability</font></font> or other claims being <font color="blue">brought against</font> the <font color="blue">practitioner</font>     utilizing the device and us</td>
    </tr>
    <tr>
      <td>The costs and <font color="blue">management</font> time we would have to     spend in defending or settling any such claims, or the payment of any award     in  <font color="blue">connection</font>  with  such claims, <font color="blue">could hurt</font> our business, results of     <font color="blue">operations</font>, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">product <font color="blue">liability</font></font>     insurance, we cannot be certain that our <font color="blue">policy will provide sufficient</font>     coverage for any claim or claims that may arise, or that we will be able to     maintain <font color="blue">such <font color="blue">insurance coverage</font> on</font> favorable <font color="blue">economic terms</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       We may be unable to attract and retain <font color="blue">management</font> and other personnel we     need to succeed</td>
    </tr>
    <tr>
      <td>The loss of any of our senior <font color="blue">management</font> or other key research, <font color="blue">development</font>,     sales, and marketing personnel, particularly if lost to <font color="blue">competitors</font>, could     hurt our future operating results</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend</font> in large     part  upon our ability to attract, retain, and <font color="blue">motivate highly skilled</font>     employees</td>
    </tr>
    <tr>
      <td>We cannot be certain that we <font color="blue">will attract</font>, retain, and motivate     <font color="blue">sufficient numbers</font> of <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>Our failure to manage future <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue"><font color="blue">joint ventures</font> <font color="blue">effective</font>ly may</font>     divert <font color="blue">management</font> attention from our core business and cause us to incur     additional debt, <font color="blue">liabilities</font> or costs</td>
    </tr>
    <tr>
      <td>We may acquire <font color="blue">businesses</font>, products, and <font color="blue">technologies</font> that <font color="blue">complement</font> or     expand  our  business</td>
    </tr>
    <tr>
      <td>We  may also consider <font color="blue">joint ventures</font> and other     <font color="blue">collaborative</font> projects</td>
    </tr>
    <tr>
      <td>We may not be able to:       ·       identify <font color="blue">appropriate <font color="blue">acquisition</font></font> or <font color="blue">joint venture candidates</font>       ·        <font color="blue">successfully</font> negotiate, finance, or integrate any <font color="blue">businesses</font>,     products, or <font color="blue">technologies</font> that we acquire       ·       <font color="blue">successfully</font> manage any <font color="blue">joint ventures</font> or <font color="blue">collaborations</font>       Furthermore, the <font color="blue">integration</font> of any <font color="blue">acquisition</font> or <font color="blue">joint venture may divert</font>     <font color="blue">management</font> time and resources</td>
    </tr>
    <tr>
      <td>If we fail to manage these <font color="blue"><font color="blue">acquisition</font>s</font> or     <font color="blue">joint ventures</font> <font color="blue">effective</font>ly, we <font color="blue">may incur debts</font> or other <font color="blue">liabilities</font> or costs     that <font color="blue">could harm</font> our operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>While we from     time to time evaluate potential <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">businesses</font>, products, and     <font color="blue">technologies</font>, consider <font color="blue">joint ventures</font> and other <font color="blue">collaborative</font> projects, and     anticipate  continuing  to  make these <font color="blue"><font color="blue">evaluation</font>s</font>, we have no present     understandings, <font color="blue">commitment</font>s, or <font color="blue">agreements with respect</font> to any <font color="blue"><font color="blue">acquisition</font>s</font>     or <font color="blue">joint ventures</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks associated with product warranties</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial costs as a result of <font color="blue">product failures</font> for which     we are <font color="blue">responsible under warranty obligations</font></td>
    </tr>
    <tr>
      <td>The expense and <font color="blue">potential unavailability</font> of <font color="blue">insurance coverage</font> for our     customers  could <font color="blue">adversely</font> affect our ability to sell our products and     <font color="blue">negatively impact</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Some of our customers and prospective customers have had <font color="blue">difficult</font>y in     procuring or maintaining <font color="blue">liability</font> insurance to cover their operation and     use of our products</td>
    </tr>
    <tr>
      <td>Medical <font color="blue">malpractice carriers</font> are <font color="blue">withdrawing coverage</font>     in  certain states or <font color="blue">substantially increasing premiums</font></td>
    </tr>
    <tr>
      <td>If this trend     continues or worsens, our <font color="blue">customers may discontinue using</font> our products and,     industry-wide, potential customers may opt against purchasing laser and     other  light-based products due to the cost of or <font color="blue">inability</font> to procure     <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 requires us to include a     report by our <font color="blue">management</font> on our <font color="blue">internal <font color="blue">control over financial</font></font> reporting</td>
    </tr>
    <tr>
      <td>Such report must contain an assessment by <font color="blue">management</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of     our <font color="blue">internal <font color="blue">control over financial</font></font> reporting as of the end of our fiscal     year  and  a  statement  as to whether or not <font color="blue">such internal control</font> is     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Such report <font color="blue">must also contain</font> a statement that our <font color="blue">independent</font>     registered  <font color="blue">public accounting firm</font> has issued an <font color="blue">attestation</font> report on     <font color="blue">management</font>’s assessment of <font color="blue">such internal control</font></td>
    </tr>
    <tr>
      <td><font color="blue">Effective </font><font color="blue">internal controls</font> are <font color="blue">necessary</font> for us to <font color="blue">provide reasonable</font>     <font color="blue">assurance with respect</font> to our financial reports and to <font color="blue">effective</font>ly prevent     fraud</td>
    </tr>
    <tr>
      <td>If  we cannot <font color="blue">provide reasonable</font> <font color="blue">assurance with respect</font> to our     financial reports and <font color="blue">effective</font>ly prevent fraud, our brand and operating     results could be harmed</td>
    </tr>
    <tr>
      <td>Internal <font color="blue">control over financial</font> reporting may not     prevent  or  detect <font color="blue">misstatements</font> because of its <font color="blue">inherent limitations</font>,     including the <font color="blue">possibility</font> of <font color="blue">human error</font>, the <font color="blue">circumvention</font> or overriding of     controls, or fraud</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Therefore,  even  <font color="blue">effective</font>  <font color="blue">internal controls</font> cannot provide absolute     <font color="blue">assurance with respect</font> to the <font color="blue">preparation</font> and <font color="blue">fair presentation</font> of financial     statements</td>
    </tr>
    <tr>
      <td>In addition, projections of any <font color="blue">evaluation</font> of <font color="blue"><font color="blue">effective</font>ness</font> of     <font color="blue">internal <font color="blue">control over financial</font></font> reporting to <font color="blue">future periods</font> are subject to     the  risk that the <font color="blue">control may become</font> inadequate because of changes in     <font color="blue">conditions</font>, or that the degree of <font color="blue">compliance with</font> the policies or procedures     may  <font color="blue">deteriorate</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of its internal     controls,  including any failure to implement required new or improved     controls, or if we experience <font color="blue"><font color="blue">difficult</font>ies</font> in their <font color="blue">implementation</font>, our     business and operating results could be harmed, and we could fail to meet     our reporting obligations, which could have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>Our efforts to <font color="blue">comply with</font> Section 404 have resulted in, and are likely to     continue  to  result in, <font color="blue">significant</font> costs, the <font color="blue">commitment</font> of time and     <font color="blue">operational resources</font> and the diversion of <font color="blue">management</font>’s attention</td>
    </tr>
  </tbody>
</table>